#Vallon #Pharmaceuticals #announces #quarter #financial #results
PHILADELPHIA, PA, Nov. 3, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs intended to reduce abuse in the treatment of central Nervous System (CNS Disorders), today announced its financial results for the quarter ended September 30, 2022.
David Baker, Vallon’s Chief Executive Officer, commented, “Our process of exploring strategic alternatives remains active and ongoing. We plan to provide an update once we have completed our assessment of potential opportunities.”
In April 2022, the company Ladenburg commissioned Thalmann & Co. Inc. to evaluate strategic alternatives. Review of strategic alternatives is ongoing and could include, among other things, evaluating the potential for a potential merger, acquisition, investment in the Company, or purchase, license or other acquisition of…
Read on GNW: Vallon Pharmaceuticals announces third quarter 2022 financial results
